PREVENTION OF LUNG FUNCTION DECLINE WITH VITAMIN E AND SELENIUM RESPIRATORY ANCI

用维生素 E 和硒呼吸 ANCI 预防肺功能衰退

• 批准号: 8174486
• 负责人: ROWAN A CHLEBOWSKI
• 金额: $ 0.55万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8174486
• 关键词: Age; Aging; Ancillary Study; Antioxidants; Authorization documentation; Blood specimen; Clinical; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Incidence; Informed Consent; Institution; Malignant neoplasm of prostate; Medical; Participant; Prevention; Randomized; Research; Research Ethics Committees; Research Personnel; Resources; Respiratory physiology; Selenium; Site; Smoker; Source; Spirometry; Structure; Testing; Time; United States National Institutes of Health; Visit; Vitamin E; Vitamins; prospective; pulmonary function; respiratory; sample collection

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The SELECT project is a multicenter randomized prospective clinical trial to assess the effect of Selenium and Vitamin E alone and in combination on the clinical incidence of prostate cancer. The RAS (IRB# 11798-01) is an ancillary study to SELECT, thus it is carried out completely within the SELECT structure. The RAS achieves its aims through collecting some additional medical information on a subset of SELECT participants. The RAS study sites are the 18 SELECT study sites. The RAS will target all participants or some of the participants, depending on the SELECT site. RAS participants must be an active SELECT participant and on Supplements at the time of registration to RAS. The overall objective of the RAS is to understand whether supplemental antioxidants can slow the loss of lung function that occurs naturally with aging. This is particularly important for smokers, who have a more rapid loss of pulmonary function with increasing age. Informed consent and PHI authorization from potential participants is a requirement prior to registration to RAS at their initial visit. All RAS participants will be followed for four years and three spirometry tests and one time blood sample collection (at the SELECT third annual visit) will be done during this period.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 SELECT项目是一项多中心随机前瞻性临床试验，旨在评估硒和维生素E单独使用和联合使用对前列腺癌临床发病率的影响。 RAS（IRB 11798-01）是SELECT的辅助研究，因此完全在SELECT结构内进行。RAS通过收集SELECT参与者子集的一些额外医疗信息来实现其目标。RAS研究中心为18家SELECT研究中心。 RAS将针对所有参与者或部分参与者，具体取决于SELECT研究中心。RAS参与者必须是活跃的SELECT参与者，并且在注册RAS时正在服用补充剂。 RAS的总体目标是了解补充抗氧化剂是否可以减缓随着衰老自然发生的肺功能丧失。这对吸烟者尤其重要，他们随着年龄的增长肺功能丧失得更快。潜在受试者在首次访视时登记到RAS之前，需要获得知情同意书和PHI授权。所有RAS受试者将接受4年随访，在此期间将进行3次肺量测定检查和1次血液样本采集（在SELECT第3次年度访视时）。